Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Salidroside for Poor Ovarian Response in IVF
NCT06990685Phase 2Not yet recruiting
- Sponsor
- Second Hospital of Shandong University
- Start
- Jun 2025
- Primary completion
- Jan 2027
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of salidroside in infertility and poor ovarian response (POR) (2 arms), sponsored by Second Hospital of Shandong University. Primary endpoint: Ongoing pregnancy rate. Planned start Jun 2025; status: not yet recruiting.
02
Drugs
salidroside
03
Conditions
infertilitypoor ovarian response (POR)
Beyond the preview
Go deeper on NCT06990685.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06990685.